Charlotte Lohmann
Directeur/Bestuurslid bij VIVORYON THERAPEUTICS N.V.
Oorsprong van het eerstegraads netwerk van Charlotte Lohmann
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Ludwig-Maximilians-Universität München
55
| College/University | Other Consumer Services | 55 |
55
| Public Company | Biotechnology | 55 |
| Public Company | Biotechnology | 22 | |
| Public Company | Pharmaceuticals: Major | 14 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Charlotte Lohmann via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| MERCK KGAA | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Director of Finance/CFO Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| Swiss Federal Institute of Technology | College/University | Graduate Degree Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
| SIEMENS AG | Industrial Machinery | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Comptroller/Controller/Auditor Public Communications Contact | |
| 2INVEST AG | Financial Conglomerates | Director/Board Member Director/Board Member Director/Board Member | |
| Freie Universität Berlin | College/University | Doctorate Degree Doctorate Degree Graduate Degree | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Ventaleon GmbH
 Ventaleon GmbH Pharmaceuticals: OtherHealth Technology Ventaleon GmbH is a biotechnology company, which engages in the development of inhaled treatments against viral infections. Its products include LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well known acetyl salicylic acid. The company was founded by Gerhard Scheuch in 2012 and is headquartered in Gauting, Germany. | Pharmaceuticals: Other | Director/Board Member Director/Board Member Chief Executive Officer | |
| Humboldt-Universität zu Berlin | College/University | Corporate Officer/Principal Undergraduate Degree Graduate Degree | |
| MEDIGENE AG | Biotechnology | Founder Director of Finance/CFO Director/Board Member | |
| Technische Universität München | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Corporate Officer/Principal | |
| IMMATICS N.V. | Biotechnology | Director/Board Member Director/Board Member Corporate Officer/Principal | |
Roche Diagnostics GmbH
 Roche Diagnostics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Roche Holding AG, Roche Diagnostics GmbH is a German company that develops innovative medicines, treatments, and diagnostics. The company is based in Mannheim, Germany. The CEOs of the company are Claudia Fleischer, Claus Haberda, Clemens Schmid. Roche Diagnostics was acquired by Roche Holding AG on January 01, 1999. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| NOVARTIS AG | Pharmaceuticals: Major | Director/Board Member Public Communications Contact Chief Tech/Sci/R&D Officer | |
febit holding GmbH
 febit holding GmbH Medical/Nursing ServicesHealth Services febit holding GmbH engages in the design and development of technologies used for DNA analysis. It specializes in technologies with applications in genomic research, RNA expression profiling, and other diagnostic and molecular biology fields. The company was founded by Markus Beier, Ramon Gueimil, Peer F. Staehler, Matthias Scheffler, and Cord F. Stähler in 2005 and is headquartered in Heidelberg, Germany. | Medical/Nursing Services | Director/Board Member Director/Board Member Chairman | |
| 4SC AG | Biotechnology | Chairman Director/Board Member Chief Executive Officer | |
Vectura GmbH
 Vectura GmbH Medical SpecialtiesHealth Technology Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany. | Medical Specialties | Director/Board Member Corporate Officer/Principal Corporate Officer/Principal | |
Immatics US, Inc.
 Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Biotechnology | Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer | |
| Julius-Maximilians-Universität Würzburg | College/University | Doctorate Degree Doctorate Degree | |
| University of Cambridge | College/University | Corporate Officer/Principal Graduate Degree | |
| Friedrich-Alexander University of Erlangen-Nuremberg | College/University | Undergraduate Degree Corporate Officer/Principal | |
| BAYER AG | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member | |
| Technical University of Berlin | College/University | Undergraduate Degree Corporate Officer/Principal | |
| Universität zu Köln | College/University | Graduate Degree Doctorate Degree | |
| The Johannes Gutenberg University of Mainz | College/University | Doctorate Degree Doctorate Degree | |
| Karlsruher Institut für Technologie | College/University | Undergraduate Degree Chief Tech/Sci/R&D Officer | |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| SEMPERIT AG HOLDING | Building Products | Director of Finance/CFO Director/Board Member | |
dievini Hopp BioTech holding GmbH & Co. KG
 dievini Hopp BioTech holding GmbH & Co. KG Investment ManagersFinance dievini Hopp BioTech holding GmbH & Co. KG operates as a private investment and consulting firm. It invests in companies related to the life and health sciences. It focuses with companies that diagnoses and provides therapy in the fields of oncology, neurology, infectious diseases, cell therapy and drug delivery systems. The company is headquartered in Walldorf, Germany. | Investment Managers | Private Equity Investor Founder | |
| Febit, Inc. | Director/Board Member Chairman | ||
Molecular Health GmbH
 Molecular Health GmbH Miscellaneous Commercial ServicesCommercial Services Part of Posbelduf Biotech AG, Molecular Health GmbH is a German management consulting company. The company is based in Heidelberg, Germany. The company was founded in 2004 by Friedrich von Bohlen und Halbach. Friedrich von Bohlen und Halbach has been the CEO since 2004. | Miscellaneous Commercial Services | Chief Executive Officer Chairman | |
| Fachhochschule Ludwigshafen am Rhein | College/University | Corporate Officer/Principal Undergraduate Degree | |
| AC IMMUNE SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| dievini Verwaltungs GmbH | Chief Executive Officer Chief Executive Officer | ||
Molecular Health, Inc.
 Molecular Health, Inc. Packaged SoftwareTechnology Services Molecular Health, Inc. operates as a cloud-based healthcare decision support technology to enable evidence-based treatment decisions. The company was founded in 2004 and is headquartered in Boston, MA. | Packaged Software | Chairman Director/Board Member | |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Biotechnology | Director/Board Member Director/Board Member | |
| Martin-Luther-Universität Halle-Wittenberg | College/University | Undergraduate Degree Doctorate Degree | |
| Harvard Business School | College/University | Undergraduate Degree Doctorate Degree | |
HBM Partners AG
 HBM Partners AG Investment ManagersFinance HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US. | Investment Managers | Private Equity Investor Founder | |
| ILLUMINA, INC. | Biotechnology | Director/Board Member Director/Board Member |
Statistieken
Internationaal
| Duitsland | 36 |
| Verenigde Staten | 8 |
| Zwitserland | 6 |
| Verenigd Koninkrijk | 2 |
| Japan | 2 |
Sectoraal
| Health Technology | 21 |
| Consumer Services | 15 |
| Commercial Services | 7 |
| Finance | 4 |
| Producer Manufacturing | 3 |
Operationeel
| Director/Board Member | 330 |
| Chief Executive Officer | 210 |
| Corporate Officer/Principal | 180 |
| Chairman | 119 |
| Independent Dir/Board Member | 58 |
Sterkste connecties
| Insiders | |
|---|---|
| Helene von Roeder | 85 |
| Christof Hettich | 40 |
| Friedrich von Bohlen und Halbach | 36 |
| Jörg Neermann | 34 |
| Daniel Camus | 31 |
| Erich Maximilian Platzer | 31 |
| Christian Rudolf Näther | 30 |
| Gerald Heinz Möller | 29 |
| Karin Eastham | 29 |
| Marcus Englert | 28 |
| Wendy Johnson | 23 |
| Thomas D. Szucs | 23 |
| Marion Weissenberger-Eibl | 22 |
| Frank Morich | 21 |
| Erik Stefan Leyers | 19 |
- Beurs
- Insiders
- Charlotte Lohmann
- Bedrijfsconnecties
